Rivaroxaban for Atrial Fibrillation & Coronary Artery Disease
.
Rivaroxaban monotherapy Shows Consistent Benefits Across All Age Groups in Atrial Fibrillation Patients with Stable Coronary Artery Disease
By Dr. Jennifer chen, Pulitzer Prize-Winning Chief editor
New research suggests that rivaroxaban, a blood thinner marketed as Xarelto, provides consistent clinical benefits for individuals with atrial fibrillation, nonetheless of age. This is particularly encouraging for older patients with atrial fibrillation and stable coronary artery disease (CAD).
A study published in JAMA revealed that rivaroxaban monotherapy – treatment with rivaroxaban alone – was as effective in preventing cardiovascular events and reducing bleeding risk as combination therapy (rivaroxaban plus an antiplatelet agent) in patients with atrial fibrillation and stable CAD. Previously, data on teh age-specific effects of rivaroxaban were limited. This new analysis aimed to address that gap.
Understanding the AFIRE Trial
The findings stem from a post-hoc analysis of the AFIRE (Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease) trial. This open-label,randomized clinical study,conducted in Japan between February 2015 and July 2018,enrolled patients with both atrial fibrillation and stable CAD.Participants had either undergone percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) at least one year prior, or had angiographically confirmed CAD that didn’t require intervention.
Researchers categorized participants into four age groups: under 70, 70-74, 75-79, and 80 and over. They then analyzed the data to determine if the efficacy and safety of rivaroxaban monotherapy varied across these age cohorts.
Key findings
The analysis showed that rivaroxaban monotherapy demonstrated consistent efficacy and safety across all age groups. This means that older patients experienced the same benefits from rivaroxaban alone as younger patients, without an increased risk of bleeding.
What Dose This Mean for Patients?
These findings are significant as they offer reassurance that rivaroxaban monotherapy is a viable treatment option for a broad range of patients with atrial fibrillation and stable CAD. Previously, concerns about increased bleeding risk in older adults might have led to a preference for combination therapy. This research suggests that, for many, a simpler regimen with rivaroxaban alone can be just as effective and may reduce the burden of multiple medications.
about Rivaroxaban (Xarelto)
Rivaroxaban is an anticoagulant medication, commonly known as a blood thinner. It works by inhibiting factor Xa, a key component in the blood clotting process. Xarelto is used to treat and prevent blood clots, including those that can occur in the legs (deep vein thrombosis) or lungs (pulmonary embolism). It is also prescribed to reduce the risk of stroke in patients with atrial fibrillation and to prevent clots after knee or hip replacement surgery.
Significant Considerations
As with any medication,rivaroxaban carries potential risks and side effects. Patients should discuss their individual circumstances with their healthcare provider to determine if rivaroxaban is the right choice for them. It’s crucial to follow your doctor’s instructions carefully and to be aware of the signs of bleeding.
Sources:
* Cleveland Clinic:[https://my.clevelandclinic